IIM
APLS

INTECH Investment Management’s Apellis Pharmaceuticals APLS Stock Holding History

INTECH Investment Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-15,342
Closed -$918K – 652
2023
Q4 		$918K Sell
15,342
-5,965
-28% -$303K 0.01% 440
2023
Q3 		$811K Buy
+21,307
New +$936K 0.01% 481

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

INTECH Investment Management's APLS Position: Q1 2024 in Review

INTECH Investment Management sold out of Apellis Pharmaceuticals (APLS) in Q1 2024, closing a stake of 15,342 shares — an estimated $918K sold.

INTECH Investment Management first reported a position in APLS in Q3 2023 and held it in 2 quarters. The position peaked at $918K in Q4 2023. 302 funds tracked by Wall St. Rank hold APLS as of Q1 2024.

  • INTECH Investment Management reported no remaining Apellis Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • INTECH Investment Management sold 15,342 Apellis Pharmaceuticals shares in Q1 2024, an estimated $918K.
  • INTECH Investment Management first reported a position in Apellis Pharmaceuticals in Q3 2023 and held it in 2 quarters.
  • INTECH Investment Management's Apellis Pharmaceuticals position peaked at $918K in Q4 2023.
  • 302 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2024.

Based on INTECH Investment Management's 13F filing for Q1 2024, filed 10 May 2024.